FDA faces nominee hearing, hiring woes and reviews of psychedelics and testosterone therapies
A Senate committee set a hearing for President Trump's pick to lead the FDA, highlighting the political scrutiny of the agency's top leadership.
New reporting reveals ongoing hiring challenges at the FDA, with vacancies affecting its ability to review submissions and enforce regulations.
The agency also convened two advisory meetings, one to discuss the potential use of psychedelic compounds for mental health conditions and another to evaluate testosterone therapy for menopausal women.
These topics underscore the FDA's expanding role in emerging therapies while it grapples with staffing and leadership issues.
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “This Week at FDA: Overton nomination hearing, FDA’s hiring challenges, and more”
read at raps ↗
comments(0)
5-min edit window · permanent after that